International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide

Pharmacological Reviews

Volumn 50, Issue 2, 1998, Pages 265-270

  Harmar, Anthony J ^a   Arimura, Akira ^b   Gozes, Illana ^c   Journot, Laurent ^d   Laburthe, Marc ^e   Pisegna, Joseph R ^f   Rawlings, Stephen R ^g   Robberecht, Patrick ^h   Said, Sami I ⁱ   Sreedharan, Sunil P ^j   Wank, Stephen A ^k   Waschek, James A ^f  

^a ROYAL EDINBURGH HOSPITAL   (United Kingdom)

^b TULANE UNIVERSITY MEDICAL CENTER   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d CCIPE   (France)

^e INSERM   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Life Science Resources   (United Kingdom)

^h UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL TISSUE; DNA SEQUENCE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; LIGAND BINDING; NOMENCLATURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; RECEPTOR GENE; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; TERMINOLOGY;

EID: 7144263741     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Adamou JE, Aiyar N, Van Horn S and Elshourbagy NA (1995) Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:385-392.
2. Arimura A and Shioda S (1995) Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors: Neuroendocrine and endocrine interaction. Front Neuroendocrinol 16:53-88.
3. Besson J, Sarrieau A, Vial M, Marie J-C, Rosselin G and Rostene W (1986) Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. Brain Res 398:329-336.
4. Brenneman DE and Eiden LE (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 73:1159-1162.
5. Chatterjee TK, Sharma RV and Fisher RA (1996) Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 271:32226-32232.
6. Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C, Vilardaga JP, Waelbroeck M and Robberecht P (1995) Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. Eur J Pharmacol 288:259-267.
7. Ciccarelli E, Vilardaga JP, Deneef P, Dipaolo E, Waelbroeck M, Bollen A and Robberecht P (1994) Properties of the VIP-PACAP type-II receptor stably expressed in CHO cells. Regul Pept 54:397-407.
8. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E and Laburthe M (1994) Human intestinal VIP receptor: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200:769-776.
9. 1 receptor: Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 271:12795-12800.
10. Delgado M, Martinez C, Johnson MC, Gomariz RP and Ganea D (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68:27-38.
11. Dickinson T, Fleetwood-Walker SM, Mitchell R and Lutz EM (1997) Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31:175-185.
12. Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM and Bloom SR (1993) Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 136:159-166
13. 1 receptor. Peptides 18:1555-1560.
14. 1 receptor agonists. Peptides 18:1539-1545.
15. 2 receptor subclass. Peptides 18:403-408
16. Gozes I, Bardea A, Reshef A, Zamostiano R, Zhukovsky S, Rubinraut S, Fridkin M and Brenneman DE (1996) Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 93:427-432.
17. Gozes I and Brenneman DE (1989) VIP: Molecular biology and neurobiological function. Mol Neurobiol 3:202-235.
18. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M and Brenneman DE (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273:161-167.
19. Gozes I, Meltzer E, Rubinrout S, Brenneman DE and Fridkin M (1989) Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist. Endocrinology 125:2945-2949.
20. Gozes I, Reshef A, Salah D, Rubinraut S and Fridkin M (1994) Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment. Endocrinology 134:2121-2125.
21. Gozes Y, Brenneman DE, Fridkin M, Asofsky R and Gozes I (1991) A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain Res 540:319-321
22. Gressens P, Hill JM, Gozes I, Fridkin M and Brenneman DE (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (Lond.) 362:155-158.
23. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M and Brenneman DE (1994) Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 94:2020-2027.
24. Hannibal J, Ding JM, Chen D, Fahrenkrug J, Larsen PJ, Gillette MU and Mikkelsen JD (1997) Pituitary adenylate cyclase-activating peptide (PACAP) in the retino-hypothalamic tract: A potential daytime regulator of the biological clock. J Neurosci 17:2637-2644.
25. Hashimoto H, Ishihara T, Shigemoto R, Mori K and Nagata S (1993) Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11:333-342.
26. Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S and Baba A (1996a) Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: An in situ hybridization study. J Comp Neurol 371:567-577.
27. Hashimoto H, Yamamoto K, Hagigara N, Ogawa N, Nishino A, Aino H, Nogi H, Imanishi K, Matsuda T and Baba A (1996b) cDNA cloning of a mouse pituitary adenylate cyclase-activating polypeptide receptor. Biochim Biophys Acta 1281:129-133.
28. Hill JM, Gozes I, Hill JL, Fridkin M and Brenneman DE (1991) Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12:187-192.
29. Hosoya M, Onda H, Ogi K, Masuda Y, Miyamoto Y, Ohtaki T, Okazaki H, Arimura A and Fujino M (1993) Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). Biochem Biophys Res Commun 194:133-143.
30. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, Miyazaki J and Seino S (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci USA 91:2679-2683.
31. Ishihara T, Shigemoto R, Mori K, Takahashi K and Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819.
32. Itoh N, Obata K, Yanaihara N and Okamoto H (1983) Human preprovasoactive intestinal polypeptide contains a novel PHI-27- like peptide, PHM-27. Nature (Lond.) 304:547-549
33. Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J and Spengler D (1995) Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor Biochem Soc Trans 23: 133-137.
34. Krempels K, Usdin TB, Harta G and Mezey E (1995) PACAP acts through VIP type 2 receptors in the rat testis. Neuropeptides 29:315-320.
35. Laburthe M, Amiranoff B, Boige N, Rouyer-Fessard C, Tatemoto K and Moroder L (1983) Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes: Comparison with PHI and secretin. FEBS Lett 159:89-92.
36. Laburthe M, Kitabgi P, Couvineau A and Amiranoff B (1993) Peptide receptors and signal transduction in the digestive tract, in Handbook of Experimental Pharmacology (Brown DR ed) vol 106, pp 133-176, Springer-Verlag, Berlin.
37. Lilling G, Wollman Y, Goldstein MN, Rubinraut S, Fridkin M, Brenneman DE and Gozes I (1994) Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 5:231-239.
38. Luis J and Said SI (1990) Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines Peptides 11:1239-1244.
39. 2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3-8.
40. 2+ through breakdown of phosphoinositides to induce catecholamine secretion: Role of IP3 in exocytosis. J Biol Chem 268:2123-2126.
41. 17]Vasoactive intestinal peptide binding sites in the rat brain. Neuroscience 23:539-565.
42. Miyamoto Y, Habata Y, Ohtaki T, Masuda Y, Ogi K, Onda H and Fujino M (1994) Cloning and expression of a complementary DNA encoding the bovine receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). Biochim Biophys Acta 1218:297-307.
43. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD and Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567-574.
44. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N and Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase-activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643-648.
45. Koller K and Sundler F (1996) Expreasion of pituitary adenylate cyclase-activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. Regul Pept 63:129-139.
46. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A and Gozes I (1993) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA 90:4345-4349.
47. Moro O and Lerner EA (1997) Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase-activating peptide type I receptor agonist. J Biol Chem 272:966-970
48. Morrow JA, Lutz EM, West KM, Fink G and Harmar AJ (1993) Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase-activating polypeptide (PACAP). FEBS Lett 329:99-105.
49. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, Tannu SA, Wasserman MA, Welton A and Bolin DR (1994a) Ro 25-1553: A novel, long-acting vasoactive intestinal peptide agonist: Part I - In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 270:1282-1288.
50. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA, Wasserman MA, Welton A and Bolin DR (1994b) Ro 25-1553: A novel, long-acting vasoactive intestinal peptide agonist: Part II - Effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270:1289-1294.
51. Ogi K, Miyamoto Y, Masuda Y, Habata Y, Hosoya M, Ohtaki T, Masuo Y, Onda H and Fujino M (1993) Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase-activating polypeptide receptor. Biochem Biophys Res Commun 196:1511-1521.
52. Ottaway CA (1987) Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 62:291-297.
53. Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J and Journot L (1996) Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem 271:22146-22151.
54. Pisegna JR and Wank SA (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci USA 90:6345-6349.
55. Pisegna JR and Wank SA (1996) Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase-activating polypeptide receptor: Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271:17267-17274.
56. Przywara DA, Guo X, Angelilli ML, Wakade TD and Wakade AR (1996) A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells. J Biol Chem 271:10545-10550.
57. Rawlings SR and Hezareh M (1996) Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland. Endocr Rev 17:4-29.
58. Rawlings SR, Piuz I, Schlegel W, Bockaert J and Journot L (1995) Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Endocrinology 136:2088-2098.
59. Reichlin S (1988) Neuroendocrine significance of vasoactive intestinal peptide. Ann N Y Acad Sci 527:431-449.
60. Robberecht P, Waelbroeck M, De Neef P, Tastenoy M, Gourlet P, Cogniaux J and Christophe J (1988) A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett 228:351-355.
61. Robberecht P, Woussen-Colle MC, De Neef P, Gourlet P, Buscail L, Vandermeers A, Vandermeers-Piret MC and Christophe J (1991) The two forms of the pituitary adenylate cyclase-activating polypeptide [PACAP(1-27) and PACAP(1-38)] interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. FEBS Lett 286:133-136.
62. Said SI (1991) Vasoactive intestinal peptide: Biologic role in health and disease. Trends Endocrinol Metab 2:107-112.
63. Said SI (1996) Vasoactive intestinal peptide and nitric oxide: Divergent roles in relation to tissue injury. Ann N Y Acad Sci 805:379-388.
64. Said SI and Mutt V (1972) Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem 28:199-204.
65. Said SI and Mutt V (1970) Polypeptide with broad biological activity: Isolation from small intestine. Science (Wash. DC) 169:1217-1218.
66. 2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience 67:409-418.
67. Shivers BD, Gores TJ, Gottschall PE and Arimura A (1991) Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128:3055-3065.
68. Sorg O and Magistretti PJ (1992) Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: Blockade by protein synthesis inhibition. J Neurosci 12:4923-4931.
69. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond.) 365:170-175.
70. Sreedharan SP, Huang JX, Cheung MC and Goetzl EJ (1995) Structure, expression, and chromosomal localization of the type 1 human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 92:2939-2943.
71. Sreedharan SP, Patel DR, Huang JX and Goetzl EJ (1993) Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 193:546-553.
72. Svoboda M, Tastenoy M, Ciccarelli E, Stievenart M and Christophe J (1993) Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptor. Biochem Biophys Res Commun 195:881-888.
73. Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P, Waelbroeck M and Robberecht P (1994) Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 206:1617-1624.
74. Tatemoto K and Mutt V (1981) Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon-secretin family. Proc Natl Acad Sci USA 78:6603-6607.
75. Usdin TB, Bonner TI and Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662-2680.
76. Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P and Waelbroeck M (1996) Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: Evidence for multiple receptor states. Mol Pharmacol 50:1596-1604.
77. Vertongen P, Schiffmann SN, Gourlet P and Robberecht P (1997) Autoradiographic visualisation of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18:1547-1554.
78. Wei Y and Mojsov S (1996) Tissue specific expression of different human receptor types for pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide: Implications for their role in human physiology. J Neuroendocrinol 8:811-817.
79. Wollman Y, Lilling G, Goldstein MN, Fridkin M and Gozes I (1993) Vasoactive intestinal peptide: A growth promoter in neuroblastoma cells. Brain Res 624:339-341.
80. Xia M, Sreedharan SP, Bolin DR, Gaufo GO and Goetzl EJ (1997) Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281:629-633.
81. Yada T, Sakurada M, Ihida K, Nakata M, Murata F, Arimura A and Kikuchi M (1994) Pituitary adenylate cyclase-activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269:1290-1293.
82. Yiangou Y, Di Marzo V, Spokes RA, Panico M, Morris HR and Bloom SR (1987) Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. J Biol Chem 262:14010-14013.